Works matching IS 03407004 AND DT 2003 AND VI 52


Results: 97
    1
    2
    3
    4
    5
    6
    7
    8

    Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use.

    Published in:
    Cancer Immunology, Immunotherapy, 2003, v. 52, n. 11, p. 699, doi. 10.1007/s00262-003-0412-9
    By:
    • Bouet-Toussaint, Françoise;
    • Patard, Jean-Jacques;
    • Gervais, Alban;
    • Genetet, Noëlle;
    • de la Pintière, Cécile Thomas;
    • Rioux-Leclercq, Nathalie;
    • Toutirais, Olivier;
    • Thirouard, Anne-Sophie;
    • Ramée, Marie-Paule;
    • Catros-Quemener, Véronique
    Publication type:
    Article
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31

    Safety, biodistribution, pharmacokinetics, and immunogenicity of <sup>99m</sup>Tc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck.

    Published in:
    Cancer Immunology, Immunotherapy, 2003, v. 52, n. 9, p. 576, doi. 10.1007/s00262-003-0396-5
    By:
    • Colnot, David R.;
    • Roos, Jan C.;
    • de Bree, Remco;
    • Wilhelm, Abraham J.;
    • Kummer, J. Alain;
    • Hanft, Gertraud;
    • Heider, Karl-Heinz;
    • Stehle, Gerd;
    • Snow, Gordon B.;
    • van Dongen, Guus A. M. S.
    Publication type:
    Article
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50